Serva Energy was featured recently in a new podcast from Drug Discovery News (DDN) highlighting the history of Actinium-225 and its potential as a promising cancer treatment. Stephanie DeMarco, PhD, the host of DDN Dialogues, takes listeners on a journey deep into the core of what makes Actinium-225 the Goldilocks of radioisotopes when it comes to killing cancer cells and why Serva is poised to significantly scale production of this exceedingly rare and valuable isotope. DDN

Serva Energy’s collaboration with the University of California—Irvine Nuclear Reactor Facility was highlighted in a recent news story (March 25, 2024 ) about how the facility is helping usher in a new generation of nuclear scientists. Having famously helped analyze the bullets that killed President John F. Kennedy, the UCI facility, with the support of UCI Assistant Professor Sarah Finkeldei, is collaborating with nuclear innovators, such as Serva, on promising solutions and

NEWS RELEASE November 1, 2023 Serva Energy’s sample measurement of the rare, cancer-killing medical isotope Actinium-225 has been validated by the Massachusetts Institute of Technology (MIT) Nuclear Research Laboratory. It’s the latest milestone in Serva’s development of commercial quantities of Actinium-225 (Ac-225) needed for next-generation Targeted Alpha Therapies. “Some of the best scientists in the world have demonstrated the power of our technology,” said Ian Horvat

Nuclear innovation was the focus of a Nuclear Science Week national expo event, Saturday, Oct. 14, with the University of California—Irvine. Members of the Serva team came together with more than 1,200 people—students, educators, and community members—for a day of learning and fun around nuclear science and innovation. “It’s always great talking with kids and members of the community about all the awesome things happening right now in nuclear,” said Ian Horvath, founder and

Partnership aims to ‘revolutionize’ isotope production in Canada Serva Energy has partnered with the Canadian Nuclear Isotope Council (CNIC), an essential advocate for the world’s supply of a diverse portfolio of isotopes. As the newest member of the CNIC, Serva seeks to engage with the growing Canadian isotope market—leveraging and developing new technologies and providing the tools necessary to produce needed isotopes for novel cancer treatments. “We are excited about this

NEWS RELEASE June 22, 2023 Tempe, AZ — Serva Energy, a nuclear innovation company, has developed a new production method to ramp up the supply of Actinium-225, a cancer-killing isotope in ultra-high demand by oncology researchers and pharmaceutical companies developing Targeted Alpha Therapies (TAT)—a promising step forward in the fight against cancer. The milestone marks the first time a commercial entity has employed a conventional nuclear reactor to produce the life-sav

This week we are headed to the University of Maryland in College Park, Maryland, for the TRTR and IGORR Research Reactor Conference. Dr. Sarah Jones, Vice President of Serva Medical, will speak as part of a panel discussion on industry collaborations. She will present on Serva’s reactor-based method for producing Actinium-225 (Ac-225) and Serva's ability to scale rapidly through strategic partnerships. “I’m really looking forward to engaging with this panel and connecting wi

U.S. support for nuclear power has reached the highest level in a decade, according to a new Gallup survey released last month. Fifty-five percent of American adults now support the use of nuclear power—“that’s up four percentage points from last year and reflects the highest level of public support for nuclear energy use in electricity since 2012,” writes Akielly Hu, a news and politics fellow with Grist. With growing bipartisan support and advances in nuclear technologies,

Recent investments in nuclear infrastructure focus on the growing demand for medical isotopes, including Actinium-225, the focus of our April newsletter. For those unfamiliar, Actinium-225 is a rare alpha-emitting radionuclide in ultra-high demand for research and development of next-generation precision cancer treatments. "Actinium-225 is the miracle drug we've been wishing for," writes Serva CEO Ian Horvath. "Actinium-225 is a radioisotope that emits alpha particles that de